News
- December 8, 2017
- Sanofi and Asahi Kasei Pharma enter license agreement for marketing of Kevzara® Subcutaneous Injection, a treatment for rheumatoid arthritis, in Japan
- November 30, 2017
- Maruho and Asahi Kasei Pharma Announce Phase 3 Clinical Study Results of Famciclovir for the Treatment of Recurrent Herpes Simplex
- October 20, 2017
- Asahi Kasei Pharma received 510(k) clearance from the FDA for Lucica® Glycated Albumin-L
- June 5, 2017
- Application for import drug registration for Flivas™ (naftopidil) in China
- May 18, 2017
- Asahi Kasei Pharma receives approval to extend treatment duration for Teribone™ osteoporosis drug
- January 12, 2017
- Announcement of marketing of Bredinin™ OD25 and Bredinin™ OD50